Matrixyl (Palmitoyl pentapeptide-4)
Aliases: Palmitoyl Pentapeptide-4 · Pal-KTTKS · Matrixyl 3000 (varijanta)
Last verified: 2026-09-23
The short version
A palmitoyl-linked collagen fragment (KTTKS) — a signal peptide that "tricks" skin into perceiving collagen damage and triggers new synthesis. One of the best-selling anti-age cosmetic peptides. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Double-blind studies show wrinkle reduction and elasticity improvement over 2–6 months. Status: research chemical. Legal cosmetic ingredient.
Identity & type
- Molecular type
- peptide
- Origin
- A palmitoyl-linked collagen fragment (KTTKS) — a signal peptide that "tricks" skin into perceiving collagen damage and triggers new synthesis.
Mechanism of action
Matrikine signaling: stimulates fibroblasts to synthesize collagen I/III/IV, fibronectin and hyaluronic acid.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for Matrixyl (Palmitoyl pentapeptide-4). Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Creams with 3–8% Matrixyl/Matrixyl 3000 twice daily. Improved texture and reduced wrinkle depth over 2–3 months; common in premium serums, the community considers it one of the most consistent cosmetic peptides.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Improved texture and reduced wrinkle depth over 2–3 months; common in premium serums, the community considers it one of the most consistent cosmetic peptides.
Protocol — official vs community
Official / label
Cosmetic ingredient (palmitoyl pentapeptide-4): 2–5% in leave-on products, twice daily.
Duration: Continuous; trial data at 2–6 months.
Collagen-fragment mimic with genuine (if modest) human data, including a published P&G trial with niacinamide.
Community (anecdotal)
2–5% serum or cream AM/PM.
- Cycle:
- Continuous.
- Break:
- None.
Pairs with retinoids and vitamin C more sensibly than with other peptides.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Double-blind studies show wrinkle reduction and elasticity improvement over 2–6 months.
Preclinical evidence
Double-blind studies show wrinkle reduction and elasticity improvement over 2–6 months.
Known risks
- Very rare irritation.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.